Subgroups

The Acute Lymphoblastic Leukaemia (ALL) Subgroup, chaired by Dr Clare Rowntree, develops research into Acute lymphoblastic leukaemia, a type of blood cancer that starts from young white blood cells called lymphocytes in the bone marrow.

Members:

Clare Rowntree, Cardiff and Vale University Health Board (CVUHB) (subgroup chair)

Thomas Fox, University College London Hospitals NHS Foundation Trust (UCLH)

Rachael Hough, University College London Hospitals NHS Foundation Trust (UCLH)

Amy Kirkwood, Senior Statistician, Cancer Research UK (CRUK) London – Clinical Trials Unit @ University College London (UCL)

David Marks, University Hospitals Bristol NHS Foundation Trust

Andrew McMillan, Consultant Haematologist, Nottingham University Hospitals NHS Trust

Tobias Menne, Newcastle upon Tyne Hospitals NHS Foundation Trust

Anthony Moorman, Professor of Genetic Epidemiology, Newcastle University

Nicholas Morley, Sheffield Teaching Hospitals NHS Foundation Trust

Gillian Murphy, NCRI Consumer Forum member

Oliver Ottmann, Professor and Head of Haematology, Cardiff University

Bella Patel, University College London (UCL)

John Reeve, NCRI Consumer Forum member

The Acute Myeloid Leukaemia (AML) Subgroup, chaired by Professor Charles Craddock, develops research into acute myeloid leukaemia, a type of blood cancer that starts from white blood cells called granulocytes or monocytes in the bone marrow.

Members:

Charles Craddock, Director of the Blood and Marrow Transplant Unit & Professor of Haemato-oncology, University of Birmingham (subgroup chair)

Sahra Ali, Hull Royal Infirmary

David Bowen, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary

Richard Castle, NCRI Consumer Forum member

Jamie Cavenagh, Queen Mary University of London

Richard Clark, University of Liverpool

Mhairi Copland, Professor of Translational Haematology and Honorary Consultant, University of Glasgow

Dominic Culligan, NHS Grampian – Aberdeen Royal Infirmary

Mike Dennis, Consultant Haematologist, Christie NHS Foundation Trust

Sylvie Freeman, King’s College London (KCL)

Ann Hunter, King’s College London (KCL)

Brian Huntly, University of Cambridge

Gail Jones, Newcastle upon Tyne Hospitals NHS Foundation Trust

Harpreet Kaur, Sheffield Teaching Hospitals NHS Foundation Trust

Asim Khwaja, University College London (UCL)

Steven Knapper, Cardiff University

Panos Kottaridis, University College London Hospitals NHS Foundation Trust (UCLH)

Robert Lown, University Hospital Southampton NHS Foundation Trust – Princess Anne Hospital

Mary McMullin, Queen’s University Belfast

Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust

Francis Mussai, Clinical Senior Lecture Consultant, University of Birmingham

Shamyla Siddique, Haematology Trials Team Leader, University of Birmingham

Paresh Vyas, Consultant Haematology, MRC Weatherall Institute of Molecular Medicine

The Chronic Lymphocytic Leukaemia (CLL) Subgroup, chaired by Dr Anna Schuh, develops research into chronic lymphocytic leukaemia, cancer that develops from lymphoid blood stem cells.

Members:

Anna Schuh, Director for Molecular Diagnostics, University of Oxford (subgroup chair)

David Allsup, Hull Royal Infirmary

Garry Bisshopp, NCRI Consumer Forum member

Adrian Bloor, Christie NHS Foundation Trust

Dena Cohen, University of Leeds

Stephen Devereux, King’s College London (KCL)

Martin Dyer, Professor of Haemato-Oncology, University Hospitals of Leicester NHS Trust

Dima El-Sharkawi, , No affiliation

Chris Fegan, Cardiff and Vale University Health Board (CVUHB)

Francesco Forconi, University of Southampton

Christopher Fox, Consultant Haematologist, Nottingham University Hospitals NHS Trust

Peter Hillmen, Professor of Experimental Haematology, University of Leeds

Parag Jasani, No affiliation

Ben Kennedy, University Hospitals of Leicester NHS Trust

Scott Marshall, South Tyneside and Sunderland NHS Foundation Trust

Nicolas Martinez, Nottingham University Hospitals NHS Trust

Chris Pepper, Cardiff University

Andrew Pettitt, Professor of Haematology Molecular and Clinical Cancer Medicine, University of Liverpool

Christopher Pocock, East Kent Hospitals University NHS Foundation Trust

Guy Pratt, University of Birmingham

Nick York, Trustee, CLL Support Association, CLL Support Association

The Chronic Myeloid Leukaemia (CML) Subgroup, chaired by Dr Dragana Milojkovic, develops research into chronic myeloid leukaemia, a type of cancer that develops from myeloid blood stem cells.

Members:

Dragana Milojkovic, Consultant Haematologist, Imperial College London (subgroup chair)

Jane Apperley, Chair of the Department of Haematology, Imperial College London

Nauman Butt, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Jenny Byrne, University of Nottingham

Richard Clark, University of Liverpool

Mhairi Copland, Professor of Translational Haematology and Honorary Consultant, University of Glasgow

Sandy Craine, King’s College London (KCL)

Joanne Ewing, Heart of England NHS Foundation Trust

Paolo Gallipolli, University of Cambridge

Andrew Goringe, King’s College London (KCL)

Brian Huntly, University of Cambridge

Stephen O’Brien, Newcastle upon Tyne Hospitals NHS Foundation Trust

Wendy Osborne, Consultant Haematologist, Newcastle upon Tyne Hospitals NHS Foundation Trust

Oliver Ottmann, Professor and Head of Haematology, Cardiff University

Seonaid Pye, Consultant Haematologist, University Hospital Southampton NHS Foundation Trust

Anupama Rao, Consultant in Paediatric Haematology, Great Ormond Street Hospital for Children NHS Foundation Trust

Kate Rothwell, Consultant in Haematology

Andres Virchis, Consultant Haematologist, University College London Hospitals NHS Foundation Trust (UCLH)

The Myelodysplastic Syndromes (MDS) Subgroup, chaired by Dr Sally Killick, develops research into conditions that can occur when the blood-forming cells in the bone marrow become abnormal.

Members:

Sally Killick, Consultant Haematologist, Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust (subgroup chair)

Rebecca Bishop, Senior Trial Coordinator, University of Birmingham

Rachel Blundred, King’s College London (KCL)

David Bowen, Leeds Teaching Hospitals NHS Trust – Leeds General Infirmary

Catherine Cargo, King’s College London (KCL)

Jamie Cavenagh, Queen Mary University of London

John Chadwick, CRUK Clinical Training Fellow, Cancer Research UK (CRUK) Manchester Centre

Tim Chevassut, King’s College London (KCL)

Dominic Culligan, NHS Grampian – Aberdeen Royal Infirmary

Christopher Dalley, King’s College London (KCL)

Mark Drummond, NHS Greater Glasgow and Clyde

Simone Green, King’s College London (KCL)

Aimie Houlton, King’s College London (KCL)

Wendy Ingram, King’s College London (KCL)

Harpreet Kaur, Sheffield Teaching Hospitals NHS Foundation Trust

Austin Kulasekararaj, King’s College London (KCL)

Judith Marsh, King’s College London (KCL)

Priyanka Mehta, University Hospitals Bristol NHS Foundation Trust

Juliet Mills, King’s College London (KCL)

Ken Mills, Queen’s University Belfast

Ghulam Mufti, King’s College London (KCL)

Jane Parker, Northampton General Hospital

Beth Payne, University College London (UCL)

Manoj Raghavan, King’s College London (KCL)

Kavita Raj, Guy’s and St Thomas’ NHS Foundation Trust

Alexander Sternberg, , King’s College London (KCL)

Paresh Vyas, Consultant Haematology, MRC Weatherall Institute of Molecular Medicine

Sophie Wintrich, King’s College London (KCL)

Dan Wiseman, Cancer Research UK (CRUK) Manchester Institute

The Myeloma Subgroup, chaired by Professor Gordon Cook, develops research into malignant tumours of the bone marrow.

Members:

Gordon Cook, University of Leeds (subgroup chair)

John Ashcroft, Mid Yorkshire Hospitals NHS trust

Holger Auner, , King’s College London (KCL)

Supratik Basu, King’s College London (KCL)

Reuben Benjamin, King’s College London (KCL)

Jenny Bird, University Hospitals Bristol NHS Foundation Trust

Stella Bowcock, Consultant Haematologist, King’s College Hospital NHS Foundation Trust

Sarah Brown, Associate Professor of Statistics in Early Phase Clinical Trials, University of Leeds

Jamie Cavenagh, Queen Mary University of London

Andy Chantry, University of Sheffield

Mike Chapman, University of Cambridge

Mark Cook, Consultant Haematologist, University Hospitals Bristol NHS Foundation Trust

Charles Crawley, Addenbrooke’s Hospital NHS Foundation Trust

Mark Drayson, King’s College London (KCL)

Shirley D’sa University College London Hospitals NHS Foundation Trust (UCLH)

Walter Gregory, Professor of Statistical Methodology in Clinical Trials, University of Leeds

Hannah Hunter, King’s College London (KCL)

Matthew Jenner, University Hospital Southampton NHS Foundation Trust

Martin Kaiser, Institute of Cancer Research (ICR)

Kamaraj Karunanithi, University Hospitals of North Midlands NHS Trust

Bhuvan Kishore, Heart of England NHS Foundation Trust

Eric Low, King’s College London (KCL)

Ceri Marrin, King’s College London (KCL)

Atul Mehta, King’s College London (KCL)

Monica Morris, Myeloma UK

Wendy Notowicz, King’s College London (KCL)

Kim Orchard, Senior Lecturer and Consultant Haematologist, University Hospital Southampton NHS Foundation Trust

Roger Owen, King’s College London (KCL)

Rakesh Popat, University College London (UCL)

Guy Pratt, University of Birmingham

Neil Rabin, Consultant Haematologist, University College London Hospitals NHS Foundation Trust (UCLH)

Karthik Ramasamy, King’s College London (KCL)

Steve Schey, King’s College London (KCL)

Clare Shaw, Assistant speciality Custer Lead, National Institute for Health Research (NIHR)

John Snowden, Sheffield Teaching Hospitals NHS Foundation Trust

Richard Soutar, University of Glasgow

Matthew Streetly, Guy’s and St Thomas’ NHS Foundation Trust

Jane Tighe, King’s College London (KCL)

Cathy Williams, Nottingham University Hospitals NHS Trust

Kwee Yong, University College London (UCL)

The Myeloproliferative Neoplasms (MPN) Subgroup, chaired by Dr Adam Mead, develops research into blood cancers that occur when the body makes too many white or red blood cells or platelets.

Members:

Adam Mead, Professor of Haematology, University of Oxford (subgroup chair)

Sahra Ali, Hull Royal Infirmary

Elizabeth Joanna Baxter, Senior Research Associate, University of Cambridge

Nauman Butt, Royal Liverpool and Broadgreen University Hospitals NHS Trust

Peter Campbell, Head Of Cancer Genetics And Genomics, Wellcome Sanger Institute

Catherine Cargo, King’s College London (KCL)

Eibjilin Conneally, Leeds Teaching Hospitals NHS Trust

Nick Cross, University of Southampton

Mark Drummond, NHS Greater Glasgow and Clyde

Andrew Duncombe, King’s College London (KCL)

Joanne Ewing, Heart of England NHS Foundation Trust

Sonia Fox, University of Birmingham

Sebastian Francis, Sheffield Teaching Hospitals NHS Foundation Trust

Rebecca Frewin, No affiliation

Anna Godfrey, King’s College London (KCL)

Tony Green, University of Cambridge

Claire Harrison, Guy’s and St Thomas’ NHS Foundation Trust

Clodagh Keohane, Mercy University Hospital

Steven Knapper, Cardiff University

Jonathan Lambert, University College London Hospitals NHS Foundation Trust (UCLH)

Donal McLornan, King’s College London (KCL)

Mary McMullin, Queen’s University Belfast

Dragana Milojkovic, Consultant Haematologist, Imperial College London

Jyoti Nangalia, University of Cambridge

Alisia O’Sullivan, King’s College London (KCL)

Deepti Radia, Guy’s and St Thomas’ NHS Foundation Trust

Ciro Rinaldi, United Lincolnshire Hospitals NHS Trust

Shekouhi Satareh, Guy’s and St Thomas’ NHS Foundation Trust

Mallika Sekhar, King’s College London (KCL)

Shamyla Siddique, Haematology Trials Team Leader, University of Birmingham

Tim Somervaille, Cancer Research UK (CRUK) Manchester Institute

Frances Wadelin, Nottingham University Hospitals NHS Trust

Jonathan Wallis, Newcastle upon Tyne Hospitals NHS Foundation Trust

Louise Wallis, Royal Brompton & Harefield NHS Foundation Trust

Claire Woodley, Guy’s and St Thomas’ NHS Foundation Trust